1. Home
  2. TNXP vs DPRO Comparison

TNXP vs DPRO Comparison

Compare TNXP & DPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$14.09

Market Cap

198.6M

Sector

Health Care

ML Signal

HOLD

Logo Draganfly Inc.

DPRO

Draganfly Inc.

HOLD

Current Price

$6.23

Market Cap

224.8M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNXP
DPRO
Founded
2007
1998
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Aerospace
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
198.6M
224.8M
IPO Year
2008
2019

Fundamental Metrics

Financial Performance
Metric
TNXP
DPRO
Price
$14.09
$6.23
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$15.00
AVG Volume (30 Days)
366.4K
1.3M
Earning Date
05-11-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
91.75
N/A
EPS
N/A
N/A
Revenue
$13,107,000.00
N/A
Revenue This Year
$558.11
$158.69
Revenue Next Year
$38.29
$131.85
P/E Ratio
N/A
N/A
Revenue Growth
29.85
N/A
52 Week Low
$11.60
$1.68
52 Week High
$69.65
$14.37

Technical Indicators

Market Signals
Indicator
TNXP
DPRO
Relative Strength Index (RSI) 51.94 60.21
Support Level $12.43 $6.15
Resistance Level $14.85 $6.74
Average True Range (ATR) 1.16 0.38
MACD 0.08 0.07
Stochastic Oscillator 49.70 98.37

Price Performance

Historical Comparison
TNXP
DPRO

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

About DPRO Draganfly Inc.

Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The two segments are Drones, and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.

Share on Social Networks: